PDMR Transaction Notification
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 27 November 2023: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), confirms that Mr Hans Peter Hasler, Chairman, acquired 2,000,000 Ordinary Shares in the Company on 21 November 2023 at a price of 6.1p per share. Mr Hasler now holds a beneficial interest in 5,500,000 Ordinary Shares.
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a. | Name | Hans Peter Hasler | ||||
| 2. | Reason for the notification | |||||
| a. | Position/status | Chairman | ||||
| b. | Initial notification /Amendment | Initial | ||||
| a. | Name | Shield Therapeutics plc | ||||
| b. | LEI | 213800G74QWY15FC3W71 | ||||
| a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293 | ||||
| b. | Nature of the transaction | Acquisition of Ordinary Shares | ||||
| c. | Price(s) and volume(s) |
| ||||
| d. | Aggregated information · Aggregated volume · Price | 2,000,000 £122,000 | ||||
| f. | Place of the transaction | AIM |
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.